This clinical trial is focused on studying a condition known as Childhood Idiopathic Nephrotic Syndrome. This is a kidney disorder that often occurs in children and is characterized by the kidneys leaking protein into the urine, leading to swelling and other symptoms. The study is comparing the effectiveness and safety of two treatments: Obinutuzumab and Mycophenolate Mofetil (also known as MMF). Obinutuzumab is a medication given through an intravenous infusion, which means it is administered directly into a vein. Mycophenolate Mofetil is available in two forms: as a powder for oral suspension and as film-coated tablets, both of which are taken by mouth.

The purpose of this study is to evaluate how well Obinutuzumab works compared to MMF in treating children with this kidney condition. Participants in the study will receive either Obinutuzumab or MMF and will be monitored over a period of time to see how their condition responds to the treatment. The study will look at various outcomes, such as the percentage of participants who achieve sustained complete remission, which means their symptoms are fully controlled for a certain period. Other aspects being studied include the number of relapses, the overall survival without relapses, and the amount of corticosteroids used during the treatment period.

Throughout the study, researchers will also monitor the participants for any side effects or changes in their health. This includes checking for any adverse events, which are unexpected medical problems that may occur during the study. The study aims to provide valuable information on the best treatment options for children with Childhood Idiopathic Nephrotic Syndrome, helping to improve their quality of life and manage their condition more effectively.